September 1st, 2025 “EURETINA-Brief”© Issue No. 324
Dear EURETINA Members, A very warm welcome to the September 1st, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted for an…
EURETINA’s
DIGITAL
NEWSLETTER
Featured Articles
1
September 1st, 2025
Latest News
September 1st, 2025 “EURETINA-Brief”© Issue No. 324
Dear EURETINA Members, A very warm welcome to the September 1st, 2025 edition of EURETINA’s…
A concept elicitation study on qualitative interviews for Retinitis pigmentosa (RP) and Choroideremia (CHM).
Researchers at the Centre Hospitalier National d’ophtalmologie des Quinze-Vingts, INSERM, Paris, France, and at the…
A systematic review of retinal gene therapy on the impact of route administrations and on serious adverse events (SAEs).
Researchers at the Biomedical Graduate Program and the Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota,…
A new gene therapy candidate – “OPGxBEST1” – has received FDA clearance from Opus Genetics for an investigational new drug application (IND) for the treatment of bestrophin-1-related IRD.
Opus Genetics (Nasdaq: IRD) have announced that the U.S. Food and Drug Administration (FDA) has…